第一三共是一家为社会可持续发展做贡献的创新型全球医疗保健公司，致力于发现、开发和提供新的标准疗法，以提高世界各地患者的生活质量。第一三共专注制药行业120余年，凭借其世界一流的科学和技术，为癌症、心血管疾病和其他医疗需求远未得到满足的疾病患者研发新的治疗方法和创新药物。如欲了解更多信息，请访问www.daiichisankyo.com<\/a>。<\/p> \n

\n \n \n \n \n \n \n \n \n \n
[1] Bardia A, et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+\/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial. ESMO Congress 2023. LBA11.<\/span><\/p> <\/td> \n <\/tr> \n
[2] National Cancer Institute. SEER cancer stat facts: female breast cancer subtypes. Accessed September 2023.<\/span><\/p> <\/td> \n <\/tr> \n
[3] Iqbal N, et al. Mol Biol Int<\/i>. 2014;852748.<\/span><\/p> <\/td> \n <\/tr> \n
[4] Lin M, et al. J Cancer<\/i>. 2020; 10.7150\/jca.48944.<\/span><\/p> <\/td> \n <\/tr> \n
[5] Lloyd M R, et al. Clin Cancer Res.<\/i> 2022; 28(5):821-30.<\/span><\/p> <\/td> \n <\/tr> \n
[6] Goldenberg D, et al. Oncotarget<\/i>. <\/i>2018;9(48): 28989-29006.<\/span><\/p> <\/td> \n <\/tr> \n
[7] Vidula N, et al. Breast Cancer Res Treat<\/i>. 2022 Aug;194(3):569-575.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
<\/p> \n
\n<\/div>"]; $("#dvExtra").html(content_array[0]);})();